The House of Lords Science and Technology Committee will take evidence from larger companies and international experts as part of its ongoing inquiry into engineering biology. The session will focus on whether larger companies are able to pull through innovative engineering biology R&D, how the UK Government’s support for the sector compares with other countries and the extent to which UK institutional investors are more concerned with financial performance than underlying technology when assessing potential investment opportunities.
Meeting details
At 10:15am: Oral evidence
Inquiry
Engineering biology
Group Technology Director at INEOS
Director of European Policy at LanzaTech UK
Head of Research at Peel Hunt
At 11:15am: Oral evidence
Inquiry
Engineering biology
Director of International Outreach at SynBioBeta
Executive Director at BioFutures, Schmidt Sciences
Head of Business Operations at Bio Base Europe Pilot Plant
Possible question areas include:
- The research in engineering biology taking place within larger companies
- The challenges partnering with or investing in smaller start-ups
- How the challenges of scaling up in the UK compare to those faced in other countries
- How regulation of the sector compares to that in other countries